Impact of the switch from original adalimumab to biosimilar adalimumab SB5 on serum drug trough levels, clinical and biological disease activity in patients with IBD

Milan Lukas  1     Veronika Pešinová  1     Martin Bortlík  1     Dana Duricova  1     Nadezda Machkova  1     Veronika Hruba  1     Martin Lukas  1     Martin Vašátko  1     Karin Malíčková    
1 ISCARE I.V.F. a.s.,Prague,Czech Republic

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing